PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000045

Oseltamivir Dosing in Critically III Patients With Severe Influenza

Identifieur interne : 000045 ( PascalFrancis/Corpus ); précédent : 000044; suivant : 000046

Oseltamivir Dosing in Critically III Patients With Severe Influenza

Auteurs : Alexander H. Flannery ; Melissa L. Thompson Bastin

Source :

The Annals of pharmacotherapy [ 1060-0280 ] ; 2014.

RBID : Pascal:14-0220950

Descripteurs français

Pascal (Inist)
- Oséltamivir, Posologie, Homme, Grippe, Soin intensif, Antiviral.

English descriptors

KwdEn :
- Antiviral, Human, Influenza, Intensive care, Oseltamivir, Posology.

Abstract

Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1060-0280`
A02	`01`			`@0 APHRER`
A03		`1`		`@0 Ann. pharmacother.`
A05				`@2 48`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Oseltamivir Dosing in Critically III Patients With Severe Influenza`
A11	`01`	`1`		`@1 FLANNERY (Alexander H.)`
A11	`02`	`1`		`@1 THOMPSON BASTIN (Melissa L.)`
A14	`01`			`@1 University of Kentucky HealthCare @2 Lexington, KY @3 USA @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 University of Kentucky College of Pharmacy @2 Lexington, KY @3 USA @Z 1 aut. @Z 2 aut.`
A20				`@1 1011-1018`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13925 @5 354000504842460080`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 27 ref.`
A47	`01`	`1`		`@0 14-0220950`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Annals of pharmacotherapy`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.
C02	`01`	`X`		`@0 002B02`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Oséltamivir @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Oseltamivir @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Oseltamivir @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Posologie @5 02`
C03	`02`	`X`	`ENG`	`@0 Posology @5 02`
C03	`02`	`X`	`SPA`	`@0 Posología @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Grippe @5 04`
C03	`04`	`X`	`ENG`	`@0 Influenza @5 04`
C03	`04`	`X`	`SPA`	`@0 Gripe @5 04`
C03	`05`	`X`	`FRE`	`@0 Soin intensif @5 05`
C03	`05`	`X`	`ENG`	`@0 Intensive care @5 05`
C03	`05`	`X`	`SPA`	`@0 Cuidado intensivo @5 05`
C03	`06`	`X`	`FRE`	`@0 Antiviral @5 23`
C03	`06`	`X`	`ENG`	`@0 Antiviral @5 23`
C03	`06`	`X`	`SPA`	`@0 Antiviral @5 23`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`03`	`X`	`ENG`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`03`	`X`	`SPA`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`04`	`X`	`FRE`	`@0 Glycosidases @2 FE`
C07	`04`	`X`	`ENG`	`@0 Glycosidases @2 FE`
C07	`04`	`X`	`SPA`	`@0 Glycosidases @2 FE`
C07	`05`	`X`	`FRE`	`@0 Glycosylases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Glycosylases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Glycosylases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`07`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`07`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`07`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`08`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 38`
C07	`08`	`X`	`ENG`	`@0 Enzyme inhibitor @5 38`
C07	`08`	`X`	`SPA`	`@0 Inhibidor enzima @5 38`
C07	`09`	`X`	`FRE`	`@0 Inhibiteur neuraminidase @2 FR @5 39`
C07	`09`	`X`	`ENG`	`@0 Neuraminidase inhibitor @2 FR @5 39`
C07	`09`	`X`	`SPA`	`@0 Inhibidor neuraminidas @2 FR @5 39`
N21				`@1 265`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0220950 INIST
ET :	Oseltamivir Dosing in Critically III Patients With Severe Influenza
AU :	FLANNERY (Alexander H.); THOMPSON BASTIN (Melissa L.)
AF :	University of Kentucky HealthCare/Lexington, KY/Etats-Unis (1 aut., 2 aut.); University of Kentucky College of Pharmacy/Lexington, KY/Etats-Unis (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	The Annals of pharmacotherapy; ISSN 1060-0280; Coden APHRER; Etats-Unis; Da. 2014; Vol. 48; No. 8; Pp. 1011-1018; Bibl. 27 ref.
LA :	Anglais
EA :	Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.
CC :	002B02; 002B05C02C
FD :	Oséltamivir; Posologie; Homme; Grippe; Soin intensif; Antiviral
FG :	Virose; Infection; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Inhibiteur neuraminidase
ED :	Oseltamivir; Posology; Human; Influenza; Intensive care; Antiviral
EG :	Viral disease; Infection; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Neuraminidase inhibitor
SD :	Oseltamivir; Posología; Hombre; Gripe; Cuidado intensivo; Antiviral
LO :	INIST-13925.354000504842460080
ID :	14-0220950

Links to Exploration step

Pascal:14-0220950

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oseltamivir Dosing in Critically III Patients With Severe Influenza</title>
<author><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name>
<affiliation><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name>
<affiliation><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0220950</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0220950 INIST</idno>
<idno type="RBID">Pascal:14-0220950</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000045</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oseltamivir Dosing in Critically III Patients With Severe Influenza</title>
<author><name sortKey="Flannery, Alexander H" sort="Flannery, Alexander H" uniqKey="Flannery A" first="Alexander H." last="Flannery">Alexander H. Flannery</name>
<affiliation><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson Bastin, Melissa L" sort="Thompson Bastin, Melissa L" uniqKey="Thompson Bastin M" first="Melissa L." last="Thompson Bastin">Melissa L. Thompson Bastin</name>
<affiliation><inist:fA14 i1="01"><s1>University of Kentucky HealthCare</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Annals of pharmacotherapy</title>
<title level="j" type="abbreviated">Ann. pharmacother.</title>
<idno type="ISSN">1060-0280</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Annals of pharmacotherapy</title>
<title level="j" type="abbreviated">Ann. pharmacother.</title>
<idno type="ISSN">1060-0280</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Human</term>
<term>Influenza</term>
<term>Intensive care</term>
<term>Oseltamivir</term>
<term>Posology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Oséltamivir</term>
<term>Posologie</term>
<term>Homme</term>
<term>Grippe</term>
<term>Soin intensif</term>
<term>Antiviral</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1060-0280</s0>
</fA01>
<fA02 i1="01"><s0>APHRER</s0>
</fA02>
<fA03 i2="1"><s0>Ann. pharmacother.</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Oseltamivir Dosing in Critically III Patients With Severe Influenza</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FLANNERY (Alexander H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>THOMPSON BASTIN (Melissa L.)</s1>
</fA11>
<fA14 i1="01"><s1>University of Kentucky HealthCare</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Kentucky College of Pharmacy</s1>
<s2>Lexington, KY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1011-1018</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13925</s2>
<s5>354000504842460080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>27 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0220950</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Annals of pharmacotherapy</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Oséltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Posologie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Posology</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Posología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Grippe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Influenza</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Gripe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Soin intensif</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Intensive care</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cuidado intensivo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Inhibiteur neuraminidase</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neuraminidase inhibitor</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Inhibidor neuraminidas</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fN21><s1>265</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0220950 INIST</NO>
<ET>Oseltamivir Dosing in Critically III Patients With Severe Influenza</ET>
<AU>FLANNERY (Alexander H.); THOMPSON BASTIN (Melissa L.)</AU>
<AF>University of Kentucky HealthCare/Lexington, KY/Etats-Unis (1 aut., 2 aut.); University of Kentucky College of Pharmacy/Lexington, KY/Etats-Unis (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The Annals of pharmacotherapy; ISSN 1060-0280; Coden APHRER; Etats-Unis; Da. 2014; Vol. 48; No. 8; Pp. 1011-1018; Bibl. 27 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To evaluate the literature for published reports regarding the efficacy of standard versus higher dosing of oseltamivir in critically ill patients with severe influenza. Data Sources: An English-language literature search was conducted using MEDLINE (1966-February 2014) using the terms oseltamivir and influenza limited to humans and adults older than 19 years. Additional articles were identified through a manual search of the references obtained from the MEDLINE search. Study Selection and Data Extraction: Articles were manually screened for inclusion related to pharmacokinetic or clinical studies comparing varying doses of oseltamivir, particularly in the critically ill patient population. Studies investigating the pharmacokinetics of oseltamivir in continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) were also included. Data Synthesis: During the 2009 HINI influenza pandemic, the World Health Organization suggested 150 mg twice daily as a consideration in critically ill patients with severe influenza. The basis for the recommendation can be traced back to animal studies investigating the H5NI virus. Three different studies in humans investigating higher doses in severe influenza have found no differences in clinical outcomes between standard and higher dosing. Pharmacokinetic studies suggest adequate absorption in critically ill patients. Although no dosage adjustment appears to be needed for ECMO patients, reduction may berequired for CRRT.. Conclusions:. Although additional data are needed for a definitive conclusion, the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients.</EA>
<CC>002B02; 002B05C02C</CC>
<FD>Oséltamivir; Posologie; Homme; Grippe; Soin intensif; Antiviral</FD>
<FG>Virose; Infection; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Inhibiteur neuraminidase</FG>
<ED>Oseltamivir; Posology; Human; Influenza; Intensive care; Antiviral</ED>
<EG>Viral disease; Infection; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Neuraminidase inhibitor</EG>
<SD>Oseltamivir; Posología; Hombre; Gripe; Cuidado intensivo; Antiviral</SD>
<LO>INIST-13925.354000504842460080</LO>
<ID>14-0220950</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000045 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0220950
   |texte=   Oseltamivir Dosing in Critically III Patients With Severe Influenza
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Oseltamivir Dosing in Critically III Patients With Severe Influenza

Oseltamivir Dosing in Critically III Patients With Severe Influenza

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri